FRAX-based intervention and assessment thresholds for osteoporosis in Iran by Khashayar, Patricia et al.
ORIGINAL ARTICLE
FRAX-based intervention and assessment thresholds for osteoporosis
in Iran
P. Khashayar1,2 & A. Keshtkar3 & A. Ostovar1 & B. Larijani4 & H. Johansson5,6 & N.C. Harvey7,8 & M. Lorentzon5,9,10 &
E. McCloskey6,11 & J.A. Kanis5,6
Received: 17 April 2019 /Accepted: 1 July 2019
# International Osteoporosis Foundation and National Osteoporosis Foundation 2019
Abstract
Summary We compared the utility of the current Iranian guidelines that recommend treatment in women with a T-score ≤ − 2.5
SD with a FRAX-based intervention threshold equivalent to women of average BMI with a prior fragility fracture. Whereas the
FRAX-based intervention threshold identified women at high fracture probability, the T-score threshold was less sensitive, and
the associated fracture risk decreased markedly with age.
Introduction The fracture risk assessment algorithm FRAX® has been recently calibrated for Iran, but guidance is needed on
how to apply fracture probabilities to clinical practice.
Methods The age-specific ten-year probabilities of a major osteoporotic fracture were calculated in women with average BMI to
determine fracture probabilities at two potential intervention thresholds. The first comprised the age-specific fracture probabilities
associated with a femoral neck T-score of − 2.5 SD, in line with current guidelines in Iran. The second approach determined age-
specific fracture probabilities that were equivalent to a womanwith a prior fragility fracture, without BMD. The parsimonious use
of BMD was additionally explored by the computation of upper and lower assessment thresholds for BMD testing.
Results When a BMD T-score ≤ − 2.5 SD was used as an intervention threshold, FRAX probabilities in women aged 50 years was
approximately two-fold higher than in women of the same age but with an average BMD and no risk factors. The relative increase in
risk associated with the BMD threshold decreased progressively with age such that, at the age of 80 years or more, a T-score of − 2.5
SD was actually protective. The 10-year probability of a major osteoporotic fracture by age, equivalent to women with a previous
fracture rose with age from 4.9% at the age of 50 years to 17%, at the age of 80 years, and identifiedwomen at increased risk at all ages.
Conclusion Intervention thresholds based on BMD alone do not effectively target women at high fracture risk, particularly in the
elderly. In contrast, intervention thresholds based on fracture probabilities equivalent to a “fracture threshold” target women at
high fracture risk.
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Introduction
Bone mineral density (BMD) measured by dual-energy X-ray
absorptiometry (DXA) is the current reference standard for the
diagnosis of osteoporosis. A femoral neck BMD that lies 2.5
standard deviations (SD) or more below the average value for
young healthy women (a T-score of < − 2.5 SD) was proposed
by the World Health Organization (WHO) as an operational
definition of osteoporosis [1–3]. The operational definition
was established primarily for descriptive epidemiology.
However, since BMD is one of the strongest predictors of
fracture risk [4, 5], many agencies worldwide adopted
BMD-based criteria for reimbursement and as intervention
thresholds. One of the currently accepted criteria for treatment
of osteoporosis in Iran is a BMD T-score ≤ − 2.5 SD, which is
also the reimbursement threshold for medical intervention [6].
Although low BMD is a strong risk factor for fracture,
many studies have shown that half or more of all patients
presenting with a fragility fracture have BMD T-scores at the
lumbar spine or the hip greater than − 2.5 SD, i.e., are not
osteoporotic (WHO 1994). Thus, the current policy can only
capture a minority of the population at high risk of fracture.
The policy is also problematic in that it assumes that all pro-
spective patients should have a BMD test and the availability
of BMD equipment is limited. In a recent survey, there were
less than 2 DXA machines per million of the general Iranian
population [7], whereas 11 or more is considered appropriate
to service the needs of a case-finding strategy [8]. This is while
national studies show that about 41% of Iranians suffer from
some degrees of bone loss and osteoporotic fractures are ex-
perienced in 359.1 cases in every 10,000 person years, which
indicates the immediate need for identifying individuals at risk
of osteoporosis and its complications [9, 10].
The advent of FRAX® provided a means of assessing frac-
ture probability that is not wholly dependent on BMD. FRAX
is a computer-based algorithm (http://www.shef.ac.uk/FRAX)
developed by the World Health Organization Collaborating
Centre for Metabolic Bone Diseases. The algorithm,
intended for primary care, calculates fracture probability
from easily obtained clinical risk factors (CRFs) in men and
women [11, 12]. The output of FRAX is the 10-year proba-
bility of a major fracture (hip, clinical spine, humerus, or wrist
fracture) and the 10-year probability of hip fracture. A FRAX
model for Iran calibrated to the Iranian population was re-
leased in 2016.
FRAX is now incorporated into many clinical guidelines
but the manner in which FRAX is used to identify cases for
treatment varies widely [13]. Many recent guidance docu-
ments have recommended the use of intervention thresholds
that are based on age-specific fracture probabilities equivalent
to a woman with a prior fragility fracture [13]. The aim of the
present analysis was to explore FRAX-based intervention
thresholds that might be used to identify Iranian women at
high fracture risk.
Methods
Intervention thresholds
In Iran, the current threshold for treatments is based on BMD
measurements using DXAwith a threshold for reimbursement
set at a T-score of − 2.5 SD. The Iranian FRAX model was
used to calculate the ten-year probabilities of a major osteo-
porotic fracture by age (in 5-year increments from the age of
40 to 90 years) in women at the threshold of osteoporosis (T-
score = − 2.5 SD). The T-score was based on the NHANES III
as a reference for BMD at the femoral neck in Caucasian
women aged 20–29 years [14]. Women were assumed to have
no other clinical risk factors that might contribute to fracture
probability. The calculation of fracture probability was made
at a body mass index (BMI) of 24 kg/m2. Changes in BMI
have little effect on predictive value for fracture risk assess-
ment in the presence of BMD [15].
Since treatment is commonly recommended in women
with a previous fragility fracture, a second intervention thresh-
old was calculated over the same age increments in women
with a prior fracture but no other clinical risk factors using the
Iranian-specific FRAX tool, without BMD and a BMI set at
24 kg/m2.
Assessment thresholds for BMD testing
The inclusion of BMD in the calculation of probability im-
proves the accuracy of the assessment [16], but the value of
BMD in a clinical context is greatest in individuals in whom
fracture probabilities lie close to an intervention threshold [12,
17, 18]. In other words, testing is confined to those in whom
there is a reasonable likelihood that individuals at high (or
low) risk would be reclassified at low (or high) risk, respec-
tively, on the basis of the BMD test. On this basis, we calcu-
lated two assessment thresholds, which were applied to the
second intervention threshold described above:
The threshold probability belowwhich neither treatment
nor a BMD test should be considered (lower assessment
threshold).
The threshold probability above which treatment may
be recommended without the need for BMD (upper as-
sessment threshold).
The lower assessment threshold was based on the 10-year
probability of a major osteoporosis fracture equivalent to
women without clinical risk factors (and a body mass index
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of 24 kg/m2 and without BMD). This is consistent with a view
in most practice guidelines that individuals without clinical
risk factors should not be considered eligible for assessment
[19].
The upper assessment threshold was set to optimize the
limited access to BMD testing in Iran. As noted above, the
risk of changing category from high risk to low risk or vice
versa when adding BMD to the estimation of fracture proba-
bility is highest close to the threshold. When patients have a
fracture probability, that is 20% or more than the intervention
threshold, almost no individuals are reclassified when proba-
bilities are recomputed with the addition of BMD to FRAX
[17]. For this reason, the upper assessment threshold was set at
1.2 times the intervention threshold.
Results
In women with no clinical risk factors, fracture probability
rose with age from 2.2% at the age of 50 years to 10% at the
age of 85 years (Fig. 1). At the age of 90 years, the fracture
probability was lower than that at age 85 years because of the
competing effect of mortality on the fracture hazard.
T-score threshold
In women aged 50 years at the threshold of osteoporosis (a
BMD T-score of − 2.5 SD), fracture probability was approxi-
mately twofold higher than that in women of the same age but
with an average BMD and no risk factors. The 10-year frac-
ture probability rose progressively with age from 4.3% at the
age of 50 years to 9.8% at the age of 80 years (see Fig. 1).
Thereafter, fracture probability decreased with age and, at the
age of 90 years, was comparable to the risk at 60 years.
Indeed, at the age of 90 years, the fracture probability for
women with a T-score of − 2.5 was lower than in women of
the same age but with no risk factors (6.1 vs. 8.6%, respec-
tively), an effect that commenced at the age of 77 years.
Prior fracture threshold
The fracture probabilities equivalent to women with a previ-
ous fragility fracture are shown in Fig. 1. The probability rose
with age, from 4.9% at the age of 50 years to 17% at the age of
80 years and decreased thereafter. Fracture probabilities using
this threshold were consistently higher than in women with no
clinical risk factors.
BMD assessment thresholds
The lower assessment threshold, below which BMD tests are
of limited value, is shown in Table 1, representing the age-
specific probabilities in women with no clinical risk factors.
The upper assessment was set at 1.2 times the intervention
threshold. The intervention threshold together with the two
assessment thresholds is shown in Table 1.
Discussion
In this study, we have examined two scenarios for the assess-
ment and treatment of women at high fracture risk based on
the Iranian FRAX tool. The first examined the current Iranian
guidelines—namely that intervention and reimbursement can
be recommended with a BMD T-score of − 2.5 SD or less. A
fixed threshold based on the T-score of − 2.5 SD has the ad-
vantage of simplicity and universality, but it also has impor-
tant limitations. The present study showed that fracture risk is
approximately doubled in women age 40–50 years with a T-
score of − 2.5 compared with women of the same age with no
clinical risk factors (see Fig. 1 and Table 2) but, with advanc-
ing age, the difference is attenuated. Indeed, from the age of
80 years, a T-score of − 2.5 SD is protective, in the sense that
the fracture probability is lower than that of the general pop-
ulation at that age. Thus, the BMD criterion for intervention
using a fixed T-score became less and less appropriate with
advancing age.
A similar phenomenon is reported in the use of FRAX
models elsewhere [20–22]. The explanation is that the average
T-score in the elderly is less than − 2.5 since the T-score of the
general population decreases with age. Thus, at the age of
50 years, the relative risk (RR) of hip fracture in a woman at
the threshold value for osteoporosis (T-score = − 2.5 SD) =
2.9. At the age of 75 years, the RR is < 1.0 [23]. Also, a low
BMD is associated with increased mortality which decreases
fracture probability. A further impediment to the use of BMD
Fig. 1 10-year probabilities of a major osteoporotic fracture (MOF; hip,
clinical spine, humerus, and forearm) calculated with the Iranian FRAX
model for women
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alone as an intervention threshold is that access to BMD test-
ing is limited in Iran [7]. These considerations suggest that
reimbursement criteria based on the T-score alone do not ef-
fectively target treatment.
Many practice guidelines recommend that women with a
prior fragility fracture should be considered for treatment [13].
In Iran, as in the USA, this eligibility clause is confined to
individuals with a recent fracture of hip or vertebra (clinical or
morphometric). If women with a prior fragility fracture merit
intervention, then women with a fracture probability that
equals or exceeds that of women with a prior fracture should
also be eligible for treatment.
In line with guidelines for the UK and Europe, we exam-
ined an intervention threshold based on the ten-year probabil-
ity of a major osteoporotic fracture for a woman with a previ-
ous fracture. The intervention threshold is age-specific and
ranged from 2.8% at the age of 40 years up to 17% at the
age of 80 years. At all ages studied, a prior fracture was asso-
ciated with a marked increase in fracture probability compared
with women with no CRFs (see Fig. 1). This increase in risk
over all relevant ages contrasts markedly with intervention
thresholds based on BMD alone.
The use of intervention thresholds based on such a
“fracture threshold” permits more women at high risk to
be considered for treatment and avoids treatment in wom-
en at low risk, thereby targeting interventions more appro-
priately than intervention thresholds based on BMD
alone. By way of an example, a woman aged 65 years
from Iran whose mother had a hip fracture and has a T-
score of − 2.0 SD has a fracture probability of 12% which
exceeds the risk in a woman of the same age with a prior
fracture and no other clinical risk factors (10%; BMI set at
25 kg/m2). Thus, this woman would be eligible for treat-
ment even in the absence of a fracture history and a BMD
test. Conversely, a woman aged 80 years with a T-score of
− 2.5 SD has a fracture probability (10%) that is well
below the intervention threshold for that age (17%). She
would not be eligible for treatment despite the presence of
densitometric osteoporosis.
Although the use of BMD tests poses some problems as a
gateway to intervention, the categorization of patients at high
or low risk is improved by the use of BMD. For this reason,
the present study provided assessment thresholds for the use
of BMD tests. Assessment thresholds for the measurement of
Table 1 Ten-year fracture
probabilities for a major
osteoporotic fracture (%) in
women by age at the intervention
threshold and the upper and lower
assessment thresholds
Age (years) Lower assessment threshold Intervention threshold Upper assessment threshold
40 1.19 2.75 3.30
45 1.64 3.68 4.42
50 2.23 4.90 5.88
55 3.07 6.58 7.90
60 4.29 8.97 10.76
65 5.67 11.49 13.79
70 7.32 13.96 16.75
75 9.40 16.48 19.78
80 10.65 17.34 20.81
85 10.06 16.28 19.54
90 8.55 13.84 16.61
Table 2 10-year probabilities of a
major osteoporotic fracture (hip,
clinical spine, humerus and
forearm) calculated with the
Iranian FRAX model for women
Age (years)
40 45 50 55 60 65 70 75 80 85 90
Major fracture
No clinical risk factors 1.2 1.6 2.2 3.1 4.3 5.7 7.3 9.4 11 10 8.6
BMD T-Score − 2.5 SDa 2.8 3.4 4.3 5.5 7.1 8.4 9.3 10 9.8 8.0 6.1
Previous fracturea 2.8 3.7 4.9 6.6 9.0 11 14 16 17 16 14
Ratios between probabilities
No CRF, T-score − 2.5 vs.
no BMD
2.3 2.1 2.0 1.8 1.7 1.5 1.3 1.1 0.9 0.8 0.7
Previous fracture vs. no CRF 2.3 2.3 2.2 2.1 2.1 1.9 1.9 1.7 1.5 1.6 1.6
a No other clinical risk factors
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BMD followed a current practice where individuals were con-
sidered to be eligible for assessment in the presence of one or
more CRF. An upper assessment threshold (i.e., a fracture
probability above which patients could be treated without re-
course to BMD) was based on optimization of the positive
predictive value of the assessment tool [24].
The concept of assessment thresholds can be illustrated in
terms of a management pathway. The management process
begins with the assessment of fracture probability and the
categorization of fracture risk on the basis of age, sex, BMI,
and clinical risk factors. On this information alone, some pa-
tients at high riskmay be offered treatment without recourse to
BMD testing. For example, as noted above, most guidelines in
Europe and North America recommend treatment in the ab-
sence of BMD in women with a previous fragility fracture.
Many would perform a BMD test, but frequently this is for
reasons other than to decide on intervention (e.g., as a baseline
for monitoring treatment). There will be other instances where
the probability will be so low that a decision not to treat can be
made without BMD. An example might be the well woman at
menopause with no clinical risk factors. Thus, not all individ-
uals require a BMD test.
The use of assessment thresholds in the context of the
Iranian population is illustrated in the management algorithm
outlined below in conjunction with Fig. 2.
1. Women with a prior fragility fracture should be consid-
ered for treatment.
2. Postmenopausal women with a clinical risk factor should
have fracture probability assessed using the FRAX tool
without measurement of BMD.
3. Individuals with probabilities of a major osteoporotic
fracture below the lower assessment threshold given in
Fig. 2 can be reassured. A further assessment may be
recommended in 5 years or less depending on the clinical
context.
4. Women with probabilities of a major osteoporotic fracture
above the upper assessment threshold or with probabili-
ties of a hip fracture above the upper limit given in Fig. 2
can be considered for treatment without BMD testing.
5. Individuals with probabilities of a major osteoporotic
fracture within the limits of the assessment thresholds
given in Fig. 2 should have a BMD test and probabilities
recomputed. If probabilities exceed the treatment thresh-
old, intervention should be considered.
The intervention thresholds proposed above are not with-
out limitations. The consequences of assessment and interven-
tion thresholds on the requirements for BMD testing have not
been explored in Iran. It will also be important to explore the
cost-effectiveness of intervention and the budget impact of
any changes in reimbursement policy. Despite these gaps, in-
tervention strategies based on fracture probabilities are more
effective than strategies reliant on the use of BMD alone in
identifying high-risk individuals for treatment and avoiding
intervention in those at low risk. An added advantage is that
BMD testing is not a prerequisite for assessment or treatment.
This feature would be particularly useful in some provinces of
Iran with limited access to DXA. Moreover, the reimburse-
ment for DXA is less than the cost of DXA, which imposes its
own financial constraints on individuals.
In summary, there is almost universal agreement that
individuals with a prior fragility fracture should be consid-
ered as candidates for osteoporosis-specific treatments,
though the fractures that qualify for this criterion differ
somewhat between countries. In individuals without a pri-
or fracture (however defined), there is a case to be made for
assessment of fracture risk in individuals with risk factors
for osteoporosis. The use of BMD as a gateway to fracture
risk assessment presents difficulties, particularly in the el-
derly in whom fracture risk is high. Some of these difficul-
ties are overcome by the use of FRAX since the tool is
designed for the assessment of fracture risk rather than
for the detection of osteoporosis. Moreover, the tool is
widely available at no or little cost and can be used with
or without the inclusion of BMD. The intervention thresh-
old explored in the present study was the age-specific frac-
ture probability in women equivalent to those with a prior
fracture but no other clinical risk factors using the Iranian-
specific FRAX tool without BMD. The same approach,
Fig. 2 Intervention thresholds for Iran as set by FRAX-based 10-year
probabilities (%) of a major osteoporotic fracture. The red area is where
treatment could be recommended, the green area is where treatment
would not be recommended, and the orange area is where BMD could
be measured (where available) to enhance the estimation of fracture risk.
The dashed line designates the intervention threshold
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first adopted in the UK [25], is now incorporated in many
national and European guidelines [19].
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